Paradigm BioCapital International Fund Ltd.'s Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Aug 5, 2024
- Accession no.
- 0001104659-24-085835
- Filed
- Aug 5, 2024, 4:30 PM ET
- Trade date
- Aug 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $35.8M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Paradigm BioCapital International Fund Ltd.CIK 0001854392 | 10% Owner |
| Paradigm Biocapital Advisors LPCIK 0001855655 | 10% Owner |
| Paradigm BioCapital Advisors GP LLCCIK 0001994082 | 10% Owner |
| Asefaw SenaiCIK 0001994183 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −1,870,499 | $14.92 | −$27,898,492.59 | 4,720,482 | Indirect | |
| Aug 1, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −529,501 | $14.92 | −$7,897,507.42 | 783,118 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.